The inhaler is packaged within a moisture-protective foil tray with a desiccant and a peelable lid in the following packs: Trelegy Ellipta 100/62.5/25 mcg 30 inhalations (60 blisters) and Trelegy ...

The FDA has approved an expanded label for GlaxoSmithKline’s new Trelegy Ellipta inhaler, allowing it to be used in a broader population of patients with chronic obstructive pulmonary disease ...

Trelegy is a key drug for GSK, and analysts predict peak sales in excess of $1billion. The company needs new revenues in respiratory diseases, as its ageing blockbuster inhaler Advair will face ...

TRENTON, N.J. - The Food and Drug Administration has approved the first inhaler combining three medicines to ease breathing in ... Monday approved sales of Trelegy Ellipta, developed jointly ...

Drug companies have until February 28, 2025, to decide on participation. The list features key medications like Trelegy Ellipta, Xtandi, and Pomalyst. This image is AI-generated and does not depict ...

Trelegy Ellipta, which treats chronic obstructive pulmonary disease and asthma; and Xtandi, which treats prostate cancer. “For some people, this is a big deal,” said Xavier Becerra ...